AccutarBio
Accutar Biotechnology is a clinical-stage biotech applying proprietary AI platforms (docking, virtual screening, retrosynthesis, ADME prediction) combined with wet lab validation to develop oral chimeric degraders in oncology. It serves pharmaceutical and biotech partners via licensing and strategic collaborations across the US and China.
- Company typePrivate
- Founded2017
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What AccutarBio does
Accutar Biotechnology Inc. is a clinical-stage biotech company applying artificial intelligence to drug discovery, headquartered in Cranbury, New Jersey with software engineering and medicinal chemistry operations in Bellevue, Washington and Mountain View, California, and roots in Shanghai. The company uses a hybrid approach combining computational drug design with wet lab validation, anchored by a proprietary AI platform comprising multiple integrated modules: Orbital (deep neural network-based molecular docking), Virtual Screen (10M+ compound library screening), ChemiRise (retrosynthesis trained on 3M+ patent organic reactions), Intelligent-SAR (lead optimization), Chemi-Net (ADME prediction), GenusOne (patent claim drafting), and InsightOne (patent metadata extraction). The platform is built on an internally developed universal force-field-based modeling methodology and has demonstrated benchmark performance including a #1 ranking out of more than 300 participants in the IDG-DREAM Drug-Kinase Binding Prediction Challenge and a 0.927 mean AUC on the DUD-E virtual screening dataset.
Accutar has translated its AI capabilities into a clinical pipeline of oral chimeric degraders against ER, AR, and BTK targets, with four programs in Phase 1 trials: AC699 and AC0682 in ER+/HER2- breast cancer, AC0176 in metastatic castration-resistant prostate cancer, and AC0676 in B-cell malignancies. AC699 and AC0176 have received FDA Fast Track designations, and AC699 Phase 1 monotherapy data presented at ASCO 2024 showed a 21% objective response rate across evaluable patients and 50% in the ESR1 mutation subgroup, with no Grade 3+ adverse events, dose reductions, or discontinuations. The company is also advancing AC4847, a PI3Kα-targeting degrader antibody conjugate that has demonstrated approximately 100-fold greater potency than the small-molecule inhibitor inavolisib in preclinical work.
The company's revenue model is anchored on strategic partnerships and platform licensing with pharmaceutical and biotech companies; the only publicly named partner is Evommune, with whom Accutar announced an AI drug discovery collaboration for chronic inflammatory diseases in November 2023. Cumulative funding exceeds US$100 million from investors including Yunfeng Capital, Coatue, 3W Healthcare Fund, ZhenFund, IDG Capital, YITU Technology, Primavera Capital Group, and CDH Investments. Pricing and contract terms are not publicly disclosed. Accutar pursues go-to-market through direct enterprise engagement with pharma and biotech (primary segment) and academic research institutions (secondary), supported by scientific conference presentations and peer-reviewed publications in journals such as Nature Communications, Nature Cancer, and Frontiers in Molecular Biosciences.
AccutarBio firmographics
Firmographics- Name
- AccutarBio
- Legal name
- Accutar Biotechnology Inc.
- Website
- https://accutarbio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Accutar Biotechnology is a clinical-stage biotech applying proprietary AI platforms (docking, virtual screening, retrosynthesis, ADME prediction) combined with wet lab validation to develop oral chimeric degraders in oncology. It serves pharmaceutical and biotech partners via licensing and strategic collaborations across the US and China.
- Ownership category
- akta.pro rank
AccutarBio industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
Keywords
Where AccutarBio is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
AccutarBio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Drug Discovery Collaboration & Licensing: Accutar generates revenue through strategic partnerships with pharmaceutical and biotech companies for AI-empowered drug discovery services, licensing of AI platforms, and co-development of novel therapeutics. The company maintains its own proprietary drug pipeline while offering platform access to partners.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
AccutarBio product offering
Product offeringCore offering
AccutarBio develops and licenses a proprietary AI-empowered drug discovery platform combining deep neural network-based computational drug design (Orbital docking, Virtual Screen, ChemiRise retrosynthesis, Intelligent-SAR, Chemi-Net ADME prediction) with wet lab validation to accelerate preclinical drug discovery. The company also advances its own clinical-stage pipeline of chimeric degrader drug candidates (AC699, AC0682, AC0176, AC0676) and licenses its AI platform to pharmaceutical partners for co-development of novel therapeutics.
Product overview
AccutarBio is a clinical-stage biotech company offering a unified AI-empowered drug discovery platform consisting of multiple integrated modules: ChemiRise (retrosynthesis engine), Orbital (docking platform), Virtual Screen (compound screening), Intelligent-SAR (lead optimization), Chemi-Net (ADME prediction), GenusOne (patent claim drafting), InsightOne (patent metadata extraction), and PatentOne AI Suite. The platform uses a hybrid approach combining computational drug design with wet lab validation to accelerate preclinical discovery from target identification through candidate nomination, reportedly reducing average preclinical timeline to one year.
Differentiator
Problem solved
Functional benefit
Products and services
- AI Drug Discovery Platform Comprehensive AI-powered preclinical drug discovery platform combining computational drug design with wet lab validation to accelerate drug discovery and reduce time and cost for pharmaceutical and biotech partners.
- ChemiRise End-to-end retrosynthesis system that proposes complete retrosynthesis routes for organic compounds rapidly and reliably, trained on a patent database of over 3 million organic reactions using graph convolutional neural networks.
- Orbital Deep neural network-based molecular docking platform enabling one-click ligand-protein docking from SMILES input, with dock-all mode scanning of all potential binding pockets in under 1 minute without traditional force field-based energy equations.
- Virtual Screen Fast and accurate virtual screening platform covering over 10 million compounds, validated by crystallization case studies for STING agonists and Mu-type GPCR ligands with new chemotypes.
- Intelligent-SAR Automatic and intelligent lead optimization platform for structure-activity relationship analysis to improve drug candidate properties during medicinal chemistry optimization.
- Chemi-Net Data-driven deep learning method for ADME (absorption, distribution, metabolism, and excretion) property prediction without requiring prior domain knowledge.
- GenusOne
Quantifiable outcome
- Reduced average preclinical drug discovery time to 1 year
- +3 more outcomes
Companies that use AccutarBio
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
AccutarBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability11 records
Feature8 records
AccutarBio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EvommunecoreStrategic partnership for discovery of novel small molecule drug candidates in chronic inflammatory diseases. Evommune leverages Accutar's proprietary AI platform combined with Evommune's expertise in oral small molecule treatments against targets causing chronic immune-mediated inflammatory diseases. Initial collaboration targets PKCθ. Terms not disclosed.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
AccutarBio competitors and assessment
Company assessmentDirect peers
- Insilico Medicine: Clinical-stage AI drug discovery company with end-to-end platform spanning target ID, generative chemistry, and clinical development. Most directly comparable in business model: proprietary pipeline plus platform licensing, with multiple IND-stage programs.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable as a publicly-traded AI biotech with multi-program pipeline and pharma partnerships (Roche, Bayer, Sanofi).
- Exscientia: AI-driven precision medicine company using Centaur Chemist and other platforms for small molecule drug discovery. Directly comparable as a platform-plus-pipeline AI biotech with pharma collaborations (BMS, Sanofi, Bayer).
- Schrödinger: Computational chemistry and materials science company with physics-based plus ML drug discovery platform. Comparable as an AI/ML drug discovery platform with internal pipeline and external licensing across pharma.
- Atomwise: AI-driven small molecule drug discovery company using AtomNet deep learning for hit identification. Comparable as an AI platform company pursuing both partnership deals and proprietary pipeline across multiple therapeutic areas.
- XtalPi: China-based AI drug discovery company combining quantum physics, AI, and robotic automation. Closely comparable given shared China-origin, AI-platform-plus-pipeline model, and major pharma partnerships (Pfizer, Boehringer Ingelheim).
- Arvinas: Clinical-stage biotech pioneering PROTAC protein degraders (vepdegestrant for ER+ breast cancer, ARV-766 for prostate cancer). Most directly comparable given overlapping degrader pipeline and same target classes (ER, AR).
- BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML for target identification and drug development. Comparable as an AI-platform-plus-pipeline biotech pursuing pharma collaborations and clinical-stage assets.
Emerging players
- Genesis Therapeutics: AI-driven drug discovery company using graph neural networks for molecular generation. Comparable as a deep-learning-focused AI biotech pursuing partnerships with major pharma (Eli Lilly, Genentech).
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company building on DeepMind's AlphaFold. Comparable as a well-capitalized AI-first drug discovery platform pursuing pharma partnerships (Eli Lilly, Novartis) at scale.
Market position
Weaknesses1 record
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
AccutarBio social profiles
Digital presenceAccutarBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
AccutarBio leadership team
Management profileNumber of profiles
Profiles8 records
AccutarBio funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AccutarBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AccutarBio
What does AccutarBio do?
AccutarBio develops and licenses a proprietary AI-empowered drug discovery platform combining deep neural network-based computational drug design (Orbital docking, Virtual Screen, ChemiRise retrosynthesis, Intelligent-SAR, Chemi-Net ADME prediction) with wet lab validation to accelerate preclinical drug discovery. The company also advances its own clinical-stage pipeline of chimeric degrader drug candidates (AC699, AC0682, AC0176, AC0676) and licenses its AI platform to pharmaceutical partners for co-development of novel therapeutics.
Is AccutarBio a public or private company?
AccutarBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was AccutarBio founded?
AccutarBio was founded in 2017. It employs 11 to 50 people.
Where is AccutarBio based?
AccutarBio is headquartered in Shanghai, China, in the Asia region.
How does AccutarBio make money?
One revenue line is on record: drug Discovery Collaboration & Licensing.
Who are AccutarBio's main competitors?
Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Exscientia, Schrödinger, Atomwise, XtalPi, Arvinas and BenevolentAI. Genesis Therapeutics is listed as an emerging player. Isomorphic Labs is listed as a broad incumbent.
Does AccutarBio have an API?
No public API is recorded for AccutarBio.
What industry is AccutarBio in?
AccutarBio's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.